Drugs / DC1 native/mutated ESR1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06691035 | Nov 2024 → Nov 2026 expected | Her2-receptor negative breast cancer | H. Lee Moffitt Cancer Center and Research Institute | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DC1 native/mutated ESR1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06691035 ↗ |
| Modality | Vaccine | “Patients will undergo apheresis of peripheral blood to collect and create DC1 vaccines.” NCT06691035 ↗ |
| Route | Other | “patients will be injected in groin nodes (or accessible breast tumor if available)” NCT06691035 ↗ |
| Target | ESR1 | “DC1 will be pulsed with ESR1 native or mutated peptides.” NCT06691035 ↗ |